Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans
Sponsor: Glycemic Index Laboratories, Inc
This PHASE1 trial investigates Insulin Resistance, Diabetes and is currently completed. Glycemic Index Laboratories, Inc leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1
-
May 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2019 — May 2020 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE1
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Glycemic Index Laboratories, Inc
- Housey Healthcare ULC
For direct contact, visit the study record on ClinicalTrials.gov .